Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lomustine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR known ✓ | P00390 | 1/20 | 0.69 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.83 |
| ▸ | PDE4A | P27815 | 1/20 | 0.83 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | BLM | P54132 | 2/20 | 0.69 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Semustine SCHEMBL8980108 | 0.93 | ALDH1A1 (0.79) | ADRA2APDE4AADRA1AALDH1A1KMT2A | |
| Lomustine SCHEMBL3995 | 0.91 | ADRA2A (1.00) | ADRA2APDE4AADRA1AALDH1A1KMT2A | |
| Lomustine SCHEMBL868328 | 0.91 | ADRA2A (1.00) | ADRA2APDE4AADRA1AALDH1A1KMT2A | |
| Lomustine SCHEMBL28262197 | 0.88 | ADRA2A (0.94) | ADRA2APDE4AADRA1AALDH1A1KMT2A | |
| Lomustine SCHEMBL28159683 | 0.87 | ADRA2A (0.91) | ADRA2APDE4AADRA1AALDH1A1KMT2A | |
| Lomustine SCHEMBL28123007 | 0.87 | ADRA2A (0.91) | ADRA2APDE4AADRA1AALDH1A1KMT2A | |
| Lomustine SCHEMBL1831239 | 0.84 | ADRA2A (0.86) | ADRA2APDE4AADRA1AALDH1A1KMT2A | |
| Carmustine SCHEMBL2047318 | 0.83 | ALDH1A1 (1.00) | ADRA2APDE4AADRA1AALDH1A1KMT2A | |
| Carmustine SCHEMBL4503 | 0.83 | ALDH1A1 (1.00) | ADRA2APDE4AADRA1AALDH1A1KMT2A | |
| Semustine SCHEMBL2350016 | 0.83 | ALDH1A1 (0.92) | ADRA2APDE4AADRA1AALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029683-B2 | Ocular implant and delivery system | ALCON INC. (CH) | 2024-07-09 | — | — | US | disclosed |
| US-20240207091-A1 | DRUG DELIVERY IMPLANTS WITH BI-DIRECTIONAL DELIVERY CAPACITY AND METHODS OF USING SAME | GLAUKOS CORP (US) | 2024-06-27 | — | — | US | disclosed |
| CN-111643129-B | Chitosan and polyethylene glycol copolymer and method and apparatus for sealing vascular perforations using the same | 通合公司 | 2024-06-11 | — | — | CN | disclosed |
| US-11992551-B2 | Implants with controlled drug delivery features and methods of using same | GLAUKOS CORPORATION (US) | 2024-05-28 | — | — | US | disclosed |
| EP-4371535-A2 | OCULAR IMPLANT | Alcon Inc. (CH) | 2024-05-22 | — | — | EP | disclosed |
| US-20240108219-A1 | INTRAOCULAR PHYSIOLOGICAL SENSOR | GLAUKOS CORPORATION | 2024-04-04 | — | — | US | disclosed |
| EP-3755287-B1 | OCULAR IMPLANT | ALCON INC (CH) | 2024-04-03 | — | — | EP | disclosed |
| US-11944573-B2 | System and method for delivering multiple ocular implants | GLAUKOS CORPORATION (US) | 2024-04-02 | — | — | US | disclosed |
| US-11938058-B2 | Ocular implant and delivery system | ALCON INC. (CH) | 2024-03-26 | — | — | US | disclosed |
| CN-117731233-A | Intraocular physiological sensor | 格拉科斯公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2013040079-A1 | INTRAOCULAR PHYSIOLOGICAL SENSOR | DOSE MEDICAL CORPORATION (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2012158910-A2 | COMPOSITIONS AND METHODS FOR TREATING RETINAL DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-22 | — | — | WO | disclosed |
| CN-102655823-A | Drug eluting ocular implant | DOSE MEDICAL CORP | 2012-09-05 | — | — | CN | disclosed |
| US-20120165933-A1 | UVEOSCLERAL DRUG DELIVERY IMPLANT AND METHODS FOR IMPLANTING THE SAME | DOSE MEDICAL CORPORATION (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2012071476-A2 | DRUG ELUTING OCULAR IMPLANT | HAFFNER DAVID (US) | 2012-05-31 | — | — | WO | disclosed |
| US-20120078362-A1 | DRUG ELUTING OCULAR IMPLANT | DOSE MEDICAL CORPORATION (US) | 2012-03-29 | — | — | US | disclosed |
| WO-2010093945-A2 | UVEOSCLERAL DRUG DELIVERY IMPLANT AND METHODS FOR IMPLANTING THE SAME | GLAUKOS CORPORATION (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2001082949-A9 | METHOD OF REDUCING SIDE EFFECTS OF CHEMOTHERAPY IN CANCER PATIENTS | SCICLONE PHARMACEUTICALS INC (US) | 2004-04-22 | — | — | WO | disclosed |
| EP-1239869-A2 | TWEAK RECEPTOR | IMMUNEX CORPORATION (US) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001045730-A2 | TWEAK RECEPTOR | IMMUNEX CORPORATION (US) | 2001-06-28 | — | — | WO | disclosed |